Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR

@article{Swan2005DopamineRD,
  title={Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR},
  author={Gary E. Swan and Ana M Valdes and Huijun Z. Ring and Taline V. Khroyan and Lisa M. Jack and Carl C. T. Ton and Susan J Curry and Tim A. McAfee},
  journal={The Pharmacogenomics Journal},
  year={2005},
  volume={5},
  pages={21-29}
}
The A1 allele of the dopamine D2 receptor gene (DRD2) is associated with a reduced number of dopamine binding sites in the brain and with the increased likelihood of substance abuse and addictive behavior. In a study of smokers enrolled in an open-label, randomized effectiveness trial, we investigated whether variants in the DRD2 receptor gene are associated with smoking cessation outcomes following treatment with a combination of bupropion SR and behavioral counseling. Adherence to treatment… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 66 references

Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers

  • EG Jonsson, MM Nothen, F Grunhage, L Farde, Y Nakashima, P Propping
  • Mol Psychiatry
  • 1999
Highly Influential
2 Excerpts

Predictors of willingness to provide buccal cells for genotyping in a smoking cessation effectiveness trial. Presented at the 10th Annual Meeting of the Society for Research on Nicotine and Tobacco

  • LM Jack, GE Swan, C Luce, HS Javitz, SJ Curry, T. McAfee
  • 2004

Bupropion SR and smoking cessation in the real world: methods for recruitment, screening, and exclusion for a field trial in a managed-care setting

  • LM Jack, GE Swan, E Thompson, SJ Curry, T McAfee, S Dacey
  • Prev Med
  • 2003

Similar Papers

Loading similar papers…